详情信息

达瑞生物加速开发基于纳米孔技术的快速、易用新型冠状病毒测序解决方案

上传时间:2020-02-20 点击率:1399

 

      在Oxford Nanopore的积极支持下,达瑞生物正在加快开发基于纳米孔技术的快速、易用的解决方案,可对引发新型冠状病毒肺炎(COVID-19)的病毒进行测序。 

 

      中国大多数专业公共卫生实验室已开始使用纳米孔技术对当下爆发的新型冠状病毒进行测序。达瑞生物和Oxford Nanopore现已开始合作,开发一种可应用于任何实验室、公共卫生机构和医院的病毒测序解决方案。

      传统的RT-PCR方法仅可样品中是否含有该病毒。与之相比,基于测序的新型冠状病毒分析可以提供更为丰富的信息。达瑞生物将凭借在中国诊断领域中丰富的专业知识,探索将纳米孔测序解决方案引入中国公共卫生和医疗系统及其潜在影响。

      基于ARTIC项目组公布的新型冠状病毒纳米孔测序工作流,达瑞生物已经开始对该解决方案进行针对性的优化和临床性能验证。ARTIC工作流程是由ARTIC Network在近期发布,利用纳米孔测序平台,可在8小时内完成从样品到获得基因组序列,时间约为其他测序工作流的三分之一。

      为了加快其在临床环境中的使用进程,达瑞生物加大了在Nanopore测序平台上优化病原微生物分析工作流程的力度。其中包括靶向基因富集,进一步缩短周期和简化过程,以便在当前疫情爆发期间对冠状病毒进行准确的检测和动态监控。

      通过开发基于纳米孔技术的新冠病毒测序方案,加速获取新型冠状病毒感染患者样本中基因组数据,一方面可协助流行病学调查,提供病毒与其他病毒的变异情况、地理分布和宿主信息,另一方面还能够支持疫苗的开发,发现耐药基因并指导临床治疗。

 

With active support from Oxford Nanopore Technologies, Darui Biotechnology is accelerating the development of a rapid, easy-to-use solution for the sequencing of the virus responsible for COVID-19 (novel coronavirus). 

 

Most specialist public health laboratories in China have started to use Oxford Nanopore technology to sequence the virus.  Darui and Oxford Nanopore have now started collaborating to develop a solution for sequencing the virus, which can then easily be used in any laboratory, public heath body and hospital – whether for a small number of samples or a very high number of samples. 

 

A sequencing-based analysis of the COVID-19 virus can deliver rich information when compared to traditional RT-PCR methods, which are designed to note only the absence or presence of the virus in a sample.  

 

Darui Biotechnology, with its substantial expertise in diagnostics in China, will explore the potential impact of introducing the solution to the public health and healthcare community in China. The company has started its first solution development based on the workflow for the rapid analysis of the COVID-19 virus that were released by the ARTIC network. This enables a sample-to-sequence in 8 hours, about a third of the time of other sequencing workflows. 

 

Darui is increasing its effort to optimise a pathogenic microorganism analysis workflow on Nanopore sequencing platform, with a view to accelerating its routine use in clinical settings. Such workflow could include target gene enrichment, shorter turnaround times and further simplified processes for accurate detection and dynamic surveillance during the current coronavirus outbreak. 

 

Faster viral genome data generation and sharing can contribute to a better public health response, providing information about virus evolution, transmission and adaptation to human hosts. Rapid availability of sequence data can also support vaccine development, discover drug-resistant genes to guide clinical treatment.

地址:广州市高新技术开发区科学城香山路19号 电话:020-32290789-174 传真:020-32290070

广州市达瑞抗体工程技术有限公司 版权所有 Powered by toprand.com